Antibody-drug conjugate · Cytotoxic, directed at B7-H3 (CD276) · developed by MacroGenics
Vobramitamab duocarmazine is an antibody-drug conjugate in which a humanized IgG1 antibody binds B7-H3 (CD276) on tumor cells and is internalized. A cleavable valine-citrulline linker releases the duocarmycin payload, which alkylates DNA and induces cell death. It is being studied in small-cell lung cancer, prostate cancer, head and neck squamous cell carcinoma, melanoma, non-small cell lung cancer and anal cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06227546 | Phase 2 | Extensive-stage Small-cell Lung Cancer | Active not recruiting | MGNX |
| NCT05551117 | Phase 2 | Castration-Resistant Prostatic Cancer | Terminated | MGNX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Extensive-stage Small-cell Lung CancerAnal CancerAnal NeoplasmAndrogen-Independent Prostatic CancerAndrogen-Insensitive Prostatic CancerAndrogen-Resistant Prostatic CancerCarcinoma, Squamous Cell of Head and NeckCastration-Resistant Prostatic CancerHead and Neck Squamous Cell CarcinomaHormone Refractory Prostatic CancerLaryngeal Squamous Cell CarcinomaMalignant MelanomaMelanomaNon-small Cell Carcinoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.
See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGNX catalysts and pipeline →